Disclosure: This article names a specific OTC hearing aid product with adaptive tinnitus masking near the end. NHI may earn a commission when readers buy through that link. See our full disclosure.
Answer in one paragraph

If you have tinnitus and hearing loss together, hearing aids are the most widely supported intervention. The 2014 AAO-HNS Clinical Practice Guideline: Tinnitus (Tunkel et al.) issued a "recommendation" (not a "strong recommendation") that clinicians recommend a hearing aid evaluation for patients with persistent, bothersome tinnitus associated with documented hearing loss. The mechanism: amplifying external sound makes the internal tinnitus signal relatively quieter, and many modern hearing aids include dedicated tinnitus sound-therapy programs. If you have tinnitus without hearing loss, hearing aids are not the appropriate first step; sound therapy and cognitive behavioral therapy are the evidence-supported routes. The most rigorous synthesis — the 2014 Cochrane review (Hoare et al.) — identified only one randomized trial meeting inclusion criteria and concluded the evidence base is too thin to make a routine-use recommendation. Tinnitus that is sudden, one-sided, pulsatile, or accompanied by neurological symptoms needs prompt clinical evaluation, not a consumer hearing aid.

Tinnitus — the perception of sound (ringing, buzzing, hissing, whooshing) without an external source — affects roughly 9.6% of U.S. adults in any 12-month period, with about 27% of those reporting symptoms for more than 15 years (Bhatt, Lin, Bhattacharyya, JAMA Otolaryngol Head Neck Surg, 2016). It commonly accompanies hearing loss, and that overlap is the central reason hearing aids are part of the conversation at all.

What the AAO-HNS Clinical Practice Guideline actually says

The 2014 AAO-HNS Clinical Practice Guideline: Tinnitus (Tunkel et al.) is the authoritative U.S. multidisciplinary guideline. It was developed by a panel of otolaryngologists, audiologists, primary care physicians, psychiatrists, geriatricians, and patient representatives, and it covers adults (18+) with primary, persistent, bothersome tinnitus.

The guideline's recommendations relevant to hearing aids:

  • Recommendation (R): "Clinicians should recommend a hearing aid evaluation for patients who have persistent, bothersome tinnitus associated with documented hearing loss." This is a "recommendation," meaning the panel judged the balance of benefit over harm to clearly favor action.
  • Strong recommendation: "Clinicians should obtain a prompt, comprehensive audiologic examination in patients with tinnitus that is unilateral, persistent (≥6 months), or associated with hearing difficulties." A strong recommendation means the panel concluded the right action is clear in nearly all circumstances.
  • Recommendation: "Clinicians should recommend cognitive behavioral therapy to patients with persistent, bothersome tinnitus." CBT does not change the loudness of tinnitus, but it consistently reduces distress and quality-of-life impact.
  • Option: "Clinicians may recommend sound therapy to patients with persistent, bothersome tinnitus." Sound therapy — low-level shaped noise, often delivered through a sound generator or a hearing aid — has moderate evidence and is widely used.

The guideline explicitly recommends against routine use of antidepressants, anticonvulsants, anxiolytics, intratympanic medications, Ginkgo biloba, melatonin, zinc, other dietary supplements, and transcranial magnetic stimulation for persistent, bothersome tinnitus. If a clinician offers any of these as the first-line approach without an evidence-based justification, the AAO-HNS guideline is the source to point to.

What the Cochrane review actually says

The 2014 Cochrane systematic review (Hoare et al.) — the most rigorous form of evidence synthesis — asked a narrower, harder question: do amplification (hearing aids) specifically improve tinnitus outcomes in patients with tinnitus and co-existing hearing loss, compared to other interventions or controls?

The review searched the major medical literature databases and identified one randomized controlled trial (91 participants) that met inclusion criteria. That trial compared hearing aid use to sound generator use and found benefit compatible with both interventions but no significant difference between them. The authors' conclusion is worth reading in full: "The current evidence base for hearing aid prescription for tinnitus is limited… whilst hearing aids are sometimes prescribed as part of tinnitus management, there is currently no evidence to support or refute their use as a more routine intervention for tinnitus."

This is not a contradiction of the AAO-HNS guideline; the two documents address different questions. AAO-HNS asks whether clinicians should recommend a hearing aid evaluation for tinnitus patients with documented hearing loss, drawing on clinical experience plus the available randomized and observational evidence. Cochrane asks whether amplification has been demonstrated, by randomized trial, to improve tinnitus outcomes specifically. The honest synthesis is: hearing aids are clinically reasonable for tinnitus with hearing loss, but the randomized trial evidence is still thin.

How hearing aids appear to help tinnitus

Two mechanisms are commonly cited:

  1. Perceptual masking. Amplifying ambient sound — ambient room noise, conversation, environmental noise — raises the level of external sound the brain perceives. Because tinnitus is an internal signal at a relatively fixed perceived loudness, raising the external floor makes the tinnitus signal proportionally quieter and less intrusive. This is the simplest and most directly observable effect.
  2. Restoration of auditory input. Hearing loss reduces the volume and detail of sound that reaches the auditory cortex. Some neural models of tinnitus suggest the brain compensates for that reduced input with increased spontaneous activity, which can be perceived as tinnitus. By restoring access to soft sounds, hearing aids may reduce that maladaptive activity. The evidence for this mechanism is suggestive rather than definitive.

Many modern prescription hearing aids also include dedicated tinnitus sound-therapy programs that play low-level shaped noise (often called fractal tones, modulated noise, or ocean-sound presets). These are programmed by an audiologist and can be adjusted to the wearer's preferred volume and spectral shape. They are not a separate device; they are a feature of the hearing aid. OTC hearing aids generally do not include these programs.

When tinnitus is a reason to see a clinician promptly

The AAO-HNS guideline issues a strong recommendation that clinicians obtain a prompt, comprehensive audiologic examination for tinnitus that is unilateral, persistent (six months or longer), or associated with hearing difficulties. The reason: tinnitus with these features can occasionally be a presenting sign of treatable or important underlying conditions — ototoxic medication effects, middle-ear conditions, vestibular schwannoma (acoustic neuroma), or cardiovascular pathology in the case of pulsatile tinnitus.

Practical red flags that warrant a clinician visit, not a consumer device:

  • Sudden tinnitus, especially with sudden hearing loss.
  • One-sided tinnitus (heard in only one ear), even if hearing seems normal.
  • Pulsatile tinnitus (pulses with your heartbeat) — needs evaluation for vascular causes.
  • Tinnitus with vertigo or dizziness.
  • Tinnitus after a head injury, ototoxic drug exposure, or loud-noise event.
  • Tinnitus with new neurological symptoms (facial weakness, balance changes, gait change).
  • Tinnitus that is rapidly progressive or accompanied by hearing change over weeks.
The honest synthesis. For an adult with gradual age-related hearing loss who also hears a steady ringing or hissing in both ears, a hearing aid evaluation is a reasonable, guideline-supported step. It is more likely to make tinnitus less intrusive than to make it louder. For tinnitus without hearing loss, a hearing aid is not the right first step; cognitive behavioral therapy and sound therapy are.

What about OTC hearing aids and AirPods Pro for tinnitus?

If your tinnitus is associated with perceived mild-to-moderate hearing loss, an FDA-regulated OTC hearing aid — or Apple's Hearing Aid Feature on AirPods Pro — uses the same primary mechanism as a prescription hearing aid: amplifying external sound to make the internal tinnitus signal relatively quieter. For some adults this is sufficient.

What OTC devices do not offer in 2026 is a clinician-programmed tinnitus sound-therapy program tailored to your audiogram. If the masking effect of amplification alone does not help, the prescription path opens up that additional layer.

What does not help (according to the evidence)

The AAO-HNS guideline panel reviewed the evidence and recommended against routine use of:

  • Antidepressants, anticonvulsants, and anxiolytics as a primary treatment for tinnitus itself (they may still be appropriate for co-existing depression or anxiety).
  • Intratympanic medications for routine tinnitus treatment.
  • Ginkgo biloba, melatonin, zinc, and other dietary supplements.
  • Transcranial magnetic stimulation for routine tinnitus treatment.

The panel issued no recommendation for or against acupuncture, indicating insufficient evidence at the time of the guideline.

Notable OTC example with built-in tinnitus masking

Most basic OTC hearing aids do not include a dedicated tinnitus sound-therapy program. One that does, at the OTC price point:

Panda Quantum

$349

Receiver-in-canal OTC device with 16-channel WDRC, multi-band adaptive noise reduction, a clinically tuned self-fitting test, Bluetooth, and an adaptive tinnitus masking program designed to play low-level shaped sound that competes with the tinnitus percept. Most useful for adults whose tinnitus accompanies documented mild-to-moderate hearing loss — the population the AAO-HNS guideline specifically addresses.

See the Panda Quantum ›

Listed because adaptive tinnitus masking is uncommon at the OTC price tier, not as a clinical recommendation. Prescription tinnitus-management devices (Widex Zen, ReSound Relief, Signia Notch Therapy, Starkey Multiflex Tinnitus Technology) remain the more researched route for adults whose tinnitus is the primary complaint.

For the full editor's pick write-up, including how-to-use guidance and the OTC vs prescription decision for tinnitus specifically: Best Hearing Aids for Tinnitus 2026 ›

The bottom line

"Do hearing aids help tinnitus?" is a question that needs the qualifying clause for whom. For adults with tinnitus and documented hearing loss, the AAO-HNS Clinical Practice Guideline supports a hearing aid evaluation; the Cochrane review is more reserved but does not contradict this. For adults with tinnitus without hearing loss, hearing aids are not the right starting point, and CBT plus sound therapy is the evidence-supported route. For tinnitus with any clinical red flag — sudden, one-sided, pulsatile, neurological symptoms — the right next step is a clinician, not a device.

Related reading. See OTC vs Prescription Hearing Aids for which path fits which person, and our glossary entry for tinnitus for definitions of the terms used here.

References

  1. Tunkel DE, Bauer CA, Sun GH, et al. Clinical Practice Guideline: Tinnitus. Otolaryngology – Head and Neck Surgery. 2014;151(2 Suppl):S1–S40. doi:10.1177/0194599814545325
  2. Hoare DJ, Edmondson-Jones M, Sereda M, Akeroyd MA, Hall D. Amplification with hearing aids for patients with tinnitus and co-existing hearing loss. Cochrane Database of Systematic Reviews. 2014;1:CD010151. doi:10.1002/14651858.CD010151.pub2
  3. Bhatt JM, Lin HW, Bhattacharyya N. Prevalence, Severity, Exposures, and Treatment Patterns of Tinnitus in the United States. JAMA Otolaryngology – Head & Neck Surgery. 2016;142(10):959–965. doi:10.1001/jamaoto.2016.1700
  4. National Institute on Deafness and Other Communication Disorders (NIDCD), NIH. Tinnitus. nidcd.nih.gov/health/tinnitus
  5. U.S. Food & Drug Administration. Medical Devices; Ear, Nose, and Throat Devices; Establishing Over-the-Counter Hearing Aids. Final Rule, effective October 17, 2022. federalregister.gov/documents/2022/08/17/2022-17230